Microorganisms,
Journal Year:
2023,
Volume and Issue:
11(6), P. 1577 - 1577
Published: June 14, 2023
The
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
outbreak
resulted
in
hundreds
of
millions
cases,
as
well
deaths
worldwide.
Coronavirus
Disease
2019
(COVID-19),
the
disease
resulting
from
exposure
to
this
pathogen,
is
characterized,
among
other
features,
by
a
pulmonary
pathology,
which
can
progress
“cytokine
storm”,
distress
(ARDS),
failure
and
death.
Vaccines
are
unsurpassed
strategy
for
prevention
protection
against
SARS-CoV-2
infection.
However,
there
still
an
extremely
high
number
severely
ill
people
at-risk
populations.
This
may
be
attributed
waning
immune
response,
variant-induced
breakthrough
infections,
unvaccinated
population,
etc.
It
therefore
importance
utilize
pharmacological-based
treatments,
despite
progression
global
vaccination
campaign.
Until
approval
Paxlovid,
efficient
highly
selective
anti-SARS-CoV-2
drug,
broad-spectrum
antiviral
agent
Lagevrio,
many
countermeasures
were,
are,
being
evaluated
clinical
trials.
Some
these
host-directed
therapies
(HDTs),
modulate
endogenic
response
virus,
confer
wide
array
pathogens.
These
could
potentially
include
Biological
Warfare
Agents
(BWAs),
lead
mass
casualties
due
severity
possible
lack
treatment.
In
review,
we
assessed
recent
literature
on
drugs
under
advanced
evaluation
COVID-19
with
broad
spectrum
activity,
including
agents
HDTs,
relevant
future
coping
BWAs,
agents,
particular
infections.
COVID,
Journal Year:
2024,
Volume and Issue:
4(11), P. 1694 - 1703
Published: Oct. 22, 2024
The
development
of
Long
COVID
is
a
complex
disease
process
that
may
be
partially
driven
by
neuroinflammation.
Antipsychotics
have
been
shown
to
exert
neuroprotective
effects
under
certain
conditions.
Our
study
aimed
determine
if
veterans
treated
with
antipsychotics
and/or
selective
serotonin
reuptake
inhibitors
(SSRIs)
for
psychiatric
condition
had
reduced
risk
developing
long-term
COVID.
We
conducted
retrospective
cohort
two
cohorts
patients
based
on
the
COVID-19
wave
in
which
patient’s
initial
infection
occurred
(Cohort
1:
alpha/beta
waves,
and
Cohort
2:
delta/omicron
waves)
stratification
age.
A
multivariate
logistic
regression
model
was
used
evaluate
association
between
use
diagnosis.
In
1,
antipsychotic
associated
43%
34%
reductions
odds
aged
<65
>65
years,
respectively.
This
second
11%
years
without
an
over
65
SSRIs
showed
no
benefit
either
age
group
or
cohort.
results
show
treatment
mental
health
reduction
COVID,
magnitude
this
varied
cohorts.
Journal of Pharmaceutical Analysis,
Journal Year:
2024,
Volume and Issue:
15(1), P. 101040 - 101040
Published: July 14, 2024
Fluvoxamine
(FXM)
is
a
well-known
selective
serotonin
reuptake
inhibitor
(SSRI)
for
treating
depression
and
has
recently
been
repurposed
efficacious
treatment
of
coronavirus
disease
2019.
Although
cyclodextrin
(CD)
encapsulation
effectively
improves
the
physicochemical
properties
structurally
diverse
SSRIs,
molecular
understanding
their
associations
deficient.
This
comprehensive
study
used
single-crystal
X-ray
diffraction
integrated
with
density
functional
theory
(DFT)
calculation
to
provide
deep
insights
into
conformationally
flexible
FXM
its
inclusion
complexation
β-CD.
analysis
revealed
first
crystallographic
evidence
uncomplexed
3FXM–H+⋅3maleate−
(1).
Three
FXM–H+
ions
are
counter-balanced
by
three
planar
maleate−
form
thin
layer
stabilized
infinite
fused
H-bond
rings
R44(12)
R64(16)
interplay
π⋅⋅⋅π,
CF⋅⋅⋅π
F⋅⋅⋅F
interactions.
For
2β-CD⋅2FXM–H+⋅maleate2−⋅23.2H2O
(2),
tail-to-tail
β-CD
dimer
encapsulates
two
4-(trifluoromethyl)phenyl
moieties,
which
charge-balanced
rare
non-planar
maleate2−
N/OH⋅⋅⋅O
H-bonds
host–guest
recognition
pattern
uniquely
observed
all
complexes
halogen
(X)-bearing
indicating
essence
X⋅⋅⋅X
interactions
shielding
X-containing
moieties
in
wall
dimer.
DFT
calculations
unveiled
that
monomeric
dimeric
β-CD–FXM
isomers
energetically
stable,
alleviates
numbness
bitterness
orally
administered
drug
as
previously
patented.
Additionally,
an
insightful
conformational
emphasizes
importance
structural
adaptation
pharmacological
functions.
Translational Neuroscience,
Journal Year:
2024,
Volume and Issue:
15(1)
Published: Jan. 1, 2024
Depression,
the
leading
cause
of
disability
worldwide,
is
known
to
be
exacerbated
by
severe
acute
respiratory
syndrome
coronavirus
2
infection,
worsening
disease
2019
(COVID-19)
outcomes.
However,
mechanisms
and
treatments
for
this
comorbidity
are
not
well
understood.
This
study
utilized
Gene
Expression
Omnibus
datasets
COVID-19
depression,
combined
with
protein-protein
interaction
networks,
identify
key
genes.
ontology
Kyoto
Encyclopedia
Genes
Genomes
analyses
were
performed
understand
gene
functions.
The
CIBERSORT
algorithm
NetworkAnalyst
used
examine
relationship
immune
cell
infiltration
expression
predict
transcription
factors
(TFs)
microRNAs
(miRNAs)
interactions.
Connectivity
Map
database
was
drug
interactions
these
TRUB1,
PLEKHA7,
FABP6
identified
as
genes
enriched
in
pathways
related
function
signaling.
Seven
TFs
nineteen
miRNAs
found
interact
Nineteen
drugs,
including
atorvastatin
paroxetine,
predicted
significantly
associated
potential
therapeutic
agents
depression.
research
provides
new
insights
into
molecular
post-COVID-19
depression
suggests
strategies,
marking
a
step
forward
understanding
treating
complex
comorbidity.
Microorganisms,
Journal Year:
2023,
Volume and Issue:
11(6), P. 1577 - 1577
Published: June 14, 2023
The
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
outbreak
resulted
in
hundreds
of
millions
cases,
as
well
deaths
worldwide.
Coronavirus
Disease
2019
(COVID-19),
the
disease
resulting
from
exposure
to
this
pathogen,
is
characterized,
among
other
features,
by
a
pulmonary
pathology,
which
can
progress
“cytokine
storm”,
distress
(ARDS),
failure
and
death.
Vaccines
are
unsurpassed
strategy
for
prevention
protection
against
SARS-CoV-2
infection.
However,
there
still
an
extremely
high
number
severely
ill
people
at-risk
populations.
This
may
be
attributed
waning
immune
response,
variant-induced
breakthrough
infections,
unvaccinated
population,
etc.
It
therefore
importance
utilize
pharmacological-based
treatments,
despite
progression
global
vaccination
campaign.
Until
approval
Paxlovid,
efficient
highly
selective
anti-SARS-CoV-2
drug,
broad-spectrum
antiviral
agent
Lagevrio,
many
countermeasures
were,
are,
being
evaluated
clinical
trials.
Some
these
host-directed
therapies
(HDTs),
modulate
endogenic
response
virus,
confer
wide
array
pathogens.
These
could
potentially
include
Biological
Warfare
Agents
(BWAs),
lead
mass
casualties
due
severity
possible
lack
treatment.
In
review,
we
assessed
recent
literature
on
drugs
under
advanced
evaluation
COVID-19
with
broad
spectrum
activity,
including
agents
HDTs,
relevant
future
coping
BWAs,
agents,
particular
infections.